These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 11109616)

  • 1. [Effects of low-intensity infrared impulse laser therapy on inflammation activity markers in patients with rheumatoid arthritis].
    Ilich-Stoianovich O; Nasonov EL; Balabanova RM
    Ter Arkh; 2000; 72(5):32-4. PubMed ID: 11109616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Neopterin: laboratory marker of cellular immunity activation in rheumatoid arthritis].
    Nasonov EL; Samsonov MIu; Chichasova NV; Imametdinova GR; Nikiforova EL; Aleksandrova EN; Ilich-Stoyanovich O; Fux D; Vaxter H
    Ter Arkh; 1998; 70(5):28-31. PubMed ID: 9644738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Neopterin: new immunological marker of autoimmune rheumatic disease].
    Nasonov EL; Samsonov MIu; Tilz G; Fuchs D
    Klin Med (Mosk); 2000; 78(8):43-6. PubMed ID: 11019525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor alpha, its soluble receptor I, and -308 gene promoter polymorphism in patients with rheumatoid arthritis with or without amyloidosis: implications for the pathogenesis of nephropathy and anemia of chronic disease in reactive amyloidosis.
    Maury CP; Liljeström M; Laiho K; Tiitinen S; Kaarela K; Hurme M
    Arthritis Rheum; 2003 Nov; 48(11):3068-76. PubMed ID: 14613268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum tumor necrosis factor alpha (TNF-alpha) concentration correlates with soluble adhesion molecules and vascular endothelial growth factor (VEGF) in rheumatoid arthritis].
    Klimiuk PA; Sierakowski S; Fiedorczyk M; Chwiećko J
    Przegl Lek; 2004; 61(2):86-9. PubMed ID: 15230147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade.
    Ingegnoli F; Fantini F; Favalli EG; Soldi A; Griffini S; Galbiati V; Meroni PL; Cugno M
    J Autoimmun; 2008 Sep; 31(2):175-9. PubMed ID: 18707846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis.
    Cardillo C; Schinzari F; Mores N; Mettimano M; Melina D; Zoli A; Ferraccioli G
    Clin Pharmacol Ther; 2006 Sep; 80(3):275-81. PubMed ID: 16952494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
    Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
    Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate.
    Parker A; Izmailova ES; Narang J; Badola S; Le T; Roubenoff R; Ginsburg GS; Maier A; Coblyn JS; Shadick NA; Weinblatt ME
    J Rheumatol; 2007 Sep; 34(9):1817-22. PubMed ID: 17696278
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function.
    Ernestam S; Hafström I; Werner S; Carlström K; Tengstrand B
    J Rheumatol; 2007 Jul; 34(7):1451-8. PubMed ID: 17477470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists.
    Motivala SJ; Khanna D; FitzGerald J; Irwin MR
    Arthritis Rheum; 2008 Feb; 58(2):376-83. PubMed ID: 18240230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Angiotensin-converting enzyme inhibition and statin treatment on inflammatory markers and endothelial functions in patients with longterm rheumatoid arthritis.
    Tikiz C; Utuk O; Pirildar T; Bayturan O; Bayindir P; Taneli F; Tikiz H; Tuzun C
    J Rheumatol; 2005 Nov; 32(11):2095-101. PubMed ID: 16265685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Tumor necrosis factor-alpha and kidney damage in rheumatoid arthritis].
    Tsybul'ko SV; Baranov AA; Borodin AG; Korshunov NI; Kirdianov SIu
    Ter Arkh; 2001; 73(5):8-11. PubMed ID: 11517757
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: cytokine modulation, safety, and clinical effects.
    Gao IK; Scholz P; Boehme MW; Norden C; Lemmel EM
    Rheumatol Int; 2002 Jun; 22(2):45-51. PubMed ID: 12070674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis.
    Popa C; Netea MG; de Graaf J; van den Hoogen FH; Radstake TR; Toenhake-Dijkstra H; van Riel PL; van der Meer JW; Stalenhoef AF; Barrera P
    J Rheumatol; 2009 Apr; 36(4):724-30. PubMed ID: 19273452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of tumour necrosis factor-alpha in rheumatoid arthritis: effects on components of rheumatoid cachexia.
    Metsios GS; Stavropoulos-Kalinoglou A; Douglas KM; Koutedakis Y; Nevill AM; Panoulas VF; Kita M; Kitas GD
    Rheumatology (Oxford); 2007 Dec; 46(12):1824-7. PubMed ID: 18032540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis.
    Park MC; Chung SJ; Park YB; Lee SK
    Scand J Rheumatol; 2008; 37(3):173-8. PubMed ID: 18465450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment.
    Ziolkowska M; Kurowska M; Radzikowska A; Luszczykiewicz G; Wiland P; Dziewczopolski W; Filipowicz-Sosnowska A; Pazdur J; Szechinski J; Kowalczewski J; Rell-Bakalarska M; Maslinski W
    Arthritis Rheum; 2002 Jul; 46(7):1744-53. PubMed ID: 12124857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.